SD-06

Research use only, not for human use.

SD-06 is a p38 MAP kinase inhibitor, inhibits p38α with IC50 of 170 nM and inhibits LPS-stimulated TNF-release in rats.

SD-06 is a p38 MAP kinase inhibitor, inhibits p38α with IC50 of 170 nM and inhibits LPS-stimulated TNF-release in rats ((83% inhibition at 1mg/kg, po).

SD 0006 clearly inhibits p38α as shown by the dose-dependent inhibition of phosphorylation of its endogenous Hsp27 substrate.

SD 0006 (0-30 mg/kg) may be an effective alternative to steroids and biologics for RA therapy.SD0006 (3.75, 7.5 and 15 mg/kg; p.o.; b.i.d.) is highly effective in attenuating SCW-induced inflammation as shown by the dose-dependent inhibition of paw swelling. Animal Model:8- to 12-week-old DBA/1 mice.Dosage:3.75, 7.5 and 15 mg/kg.Administration:Orally twice daily.Result:Inhibited the transcription of several inflammatory mediators to prevent joint swelling and bone destruction and to preserve bone density.

SD 06 | SD06

MAPK/ERK Signaling

p38 MAPK

p38 MAPK

Inflammation/Immunology

——

271576-80-8

397.8581

C20H20ClN5O2

>98% (HPLC)

DMSO: ≥ 29 mg/mL

OCC(N1CCC(C2=C(C3=NC=NC=C3)C(C4=CC=C(Cl)C=C4)=NN2)CC1)=O

Ethanone, 1-[4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-piperidinyl]-2-hydroxy-

(-20℃)

With Ice Pack

≥ 2 years